Literature DB >> 6436370

Modulation induction of the T3 antigen by OKT3 antibody is monocyte dependent.

E A Rinnooy Kan, E Platzer, K Welte, C Y Wang.   

Abstract

We investigated the influence of monocytes on the susceptibility of the T3 antigen on human T cells to modulation induction by OKT3 antibody. In the absence of monocytes, the T3 antigen was only minimally susceptible to modulation. After the addition of 20% monocytes to the culture, however, complete modulation was readily observed. Furthermore, we found that even in the absence of OKT3 antibody, monocytes were able to down-regulate the expression of the T3 antigen, although to a lesser extent. The ability of monocytes to enhance antigenic modulation proved to be a more general phenomenon. Each individual T cell antigen, however, differed in its susceptibility to modulation by antibody, monocytes, or both, thereby establishing its own characteristic pattern. In addition, after complete modulation of the T3 antigen, the addition of monocytes to the culture thereafter had a distinct inhibitory effect on the reexpression of the T3 antigen. Monocyte enhancement of T3 modulation is significantly reduced when using the OKT3 F(ab')2 fragment, as is OKT3 mitogenesis. After pulsing the monocytes with OKT3 antibody before adding them to the culture, T3 modulation became nearly complete even in the absence of added OKT3 antibody. Monocyte-induced modulation proved not to be MHC restricted, thus allowing for comparative analysis of this effect between monocytes and other cell types. A moderate, however, incomplete modulation enhancement was observed with the human monocyte cell line U937 and with Daudi cells. This finding proved to coincide with the distinct ability of these cell lines to bind OKT3 antibody by their Fc receptors, as was the case with monocytes. In contrast, neither Fc receptor binding nor T3 modulation enhancement was observed with the cell lines Cess and G7. In addition, no effective T3 modulation was observed with glutaraldehyde-fixed monocytes. The overall results seem to indicate that effective modulation of the T3 antigen by OKT3 antibody requires the active participation of Fc receptors on monocytes.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6436370

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

1.  Induction of interleukin 2 receptiveness and proliferation in resting peripheral T cells by monoclonal anti-CD3 (T3) antibodies does not require the presence of macrophages.

Authors:  L A Stingl; A Sinska; U Landesmann; J S Smolen
Journal:  Clin Exp Immunol       Date:  1987-04       Impact factor: 4.330

2.  Stimulation of human monocytes by anti-CD3 monoclonal antibody: induction of inflammatory mediator release via immobilization of Fc receptor by adsorbed immunoglobulin and T-lymphocytes.

Authors:  T Hoffman; A K Tripathi; Y L Lee; E F Lizzio; E Bonvini
Journal:  Inflammation       Date:  1992-12       Impact factor: 4.092

3.  Functional localization of an exocytosis-triggering G-protein in human cytotoxic T lymphocytes.

Authors:  H W Mittrücker; B Fleischer
Journal:  Immunology       Date:  1992-08       Impact factor: 7.397

4.  A new HLA-linked T cell membrane molecule, related to the beta chain of the clonotypic receptor, is associated with T3.

Authors:  Y Bushkin; D N Posnett; B Pernis; C Y Wang
Journal:  J Exp Med       Date:  1986-08-01       Impact factor: 14.307

5.  Influence of Irradiated Peripheral Blood Mononuclear Cells on Both Ex Vivo Proliferation of Human Natural Killer Cells and Change in Cellular Property.

Authors:  María Delso-Vallejo; Jutta Kollet; Ulrike Koehl; Volker Huppert
Journal:  Front Immunol       Date:  2017-07-24       Impact factor: 7.561

6.  The secreted protein Cowpox Virus 14 contributes to viral virulence and immune evasion by engaging Fc-gamma-receptors.

Authors:  Ravi F Iyer; David M Edwards; Philipp Kolb; Hans-Peter Raué; Chris A Nelson; Megan L Epperson; Mark K Slifka; Jeffrey C Nolz; Hartmut Hengel; Daved H Fremont; Klaus Früh
Journal:  PLoS Pathog       Date:  2022-09-19       Impact factor: 7.464

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.